- Home
- NPCE vs CATX Comparison
NPCE vs CATX Comparison
Compare NPCE & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCE
- CATX
- Stock Information
- Founded
- NPCE 1997
- CATX 1983
- Country
- NPCE United States
- CATX United States
- Employees
- NPCE N/A
- CATX N/A
- Industry
- NPCE Medical Specialities
- CATX Medical/Dental Instruments
- Sector
- NPCE Health Care
- CATX Health Care
- Exchange
- NPCE Nasdaq
- CATX Nasdaq
- Market Cap
- NPCE 292.9M
- CATX 239.0M
- IPO Year
- NPCE 2021
- CATX N/A
- Fundamental
- Price
- NPCE $9.73
- CATX $3.47
- Analyst Decision
- NPCE Strong Buy
- CATX Strong Buy
- Analyst Count
- NPCE 6
- CATX 11
- Target Price
- NPCE $16.67
- CATX $12.90
- AVG Volume (30 Days)
- NPCE 214.9K
- CATX 703.2K
- Earning Date
- NPCE 08-12-2025
- CATX 08-13-2025
- Dividend Yield
- NPCE N/A
- CATX N/A
- EPS Growth
- NPCE N/A
- CATX N/A
- EPS
- NPCE N/A
- CATX N/A
- Revenue
- NPCE $88,570,000.00
- CATX $1,235,000.00
- Revenue This Year
- NPCE $22.13
- CATX N/A
- Revenue Next Year
- NPCE $6.07
- CATX N/A
- P/E Ratio
- NPCE N/A
- CATX N/A
- Revenue Growth
- NPCE 23.32
- CATX N/A
- 52 Week Low
- NPCE $5.45
- CATX $1.60
- 52 Week High
- NPCE $18.98
- CATX $16.31
- Technical
- Relative Strength Index (RSI)
- NPCE 61.04
- CATX 45.81
- Support Level
- NPCE $8.88
- CATX $3.20
- Resistance Level
- NPCE $8.99
- CATX $3.68
- Average True Range (ATR)
- NPCE 0.39
- CATX 0.24
- MACD
- NPCE 0.15
- CATX -0.01
- Stochastic Oscillator
- NPCE 93.98
- CATX 40.77
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.